We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
- Authors
Advani, Anjali S.; Tse, William; Li, Hong; Jia, Xuefei; Elson, Paul; Cooper, Brenda; Ali-Osman, Francis; Park, Jino; Rao, Arati V.; Rizzieri, David A.; Wang, Eunice S.; Cotta, Claudiu V.; Kalaycio, Matt; Sobecks, Ronald M.; Rouphail, Basel; Maciejewski, Jaroslaw P.; Fensterl, Jaime; Carew, Jennifer S.; Foster, Bethany; Rush, Mary Lynn
- Abstract
<bold>Introduction: </bold>Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target.<bold>Materials and Methods: </bold>Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls.<bold>Results: </bold>The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors.<bold>Conclusions: </bold>Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, Issue 2, p113
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2020.11.018